Part­ner Com­pa­ny

Chi­nese phar­ma­ceu­ti­cal com­pa­ny

Tar­get Raw

Mate­r­i­al

(Ingre­di­ents)

Nano Health Sup­ple­ments and Nano Phar­ma­ceu­ti­cal Semi-fin­ished Prod­ucts

Busi­ness

Moti­va­tion

NPG Sci­ence has com­plet­ed the ini­tial ver­i­fi­ca­tion indi­cat­ing the poten­tial to pro­duce pre­mi­um phar­ma­ceu­ti­cal prod­ucts by nano-engi­neer­ing phar­ma­ceu­ti­cal raw mate­ri­als from Chi­nese phar­ma­ceu­ti­cal com­pa­ny. The plan is to export nano raw mate­ri­als and nano semi-fin­ished prod­ucts by March 2024, focus­ing on nano health sup­ple­ments and phar­ma­ceu­ti­cal semi-fin­ished prod­ucts.

NPG Sci­ence Tasks,

Respon­si­bil­i­ties

Export of Nano Semi-fin­ished Prod­ucts

Chi­nese phar­ma­ceu­ti­cal com­pa­ny Tasks, Respon­si­bil­i­ties

Prod­uct Man­u­fac­tur­ing and Glob­al Dis­tri­b­u­tion

Con­tract Amount

(15 mil­lion USD)

The des­ig­nat­ed price by our com­pa­ny per unit of pack­ag­ing for semi-fin­ished prod­ucts

Expect­ed

Rev­enue

NPG Sci­ence : 1.5 mil­lion USD annu­al rev­enue (ini­tial quan­ti­ty)

Nano-mate­r­i­al

Sup­ply

Unit Price

<Export>

Chi­nese phar­ma­ceu­ti­cal com­pa­ny, rec­og­nized by the Chi­nese gov­ern­ment as a des­ig­nat­ed health­care insur­ance com­pa­ny, enables prod­ucts pur­chased by Chi­nese phar­ma­ceu­ti­cal com­pa­ny to qual­i­fy for health insur­ance cov­er­age. This facil­i­tates smooth sales and max­i­mizes rev­enue, ensur­ing sta­ble prof­itabil­i­ty and long-term via­bil­i­ty for the busi­ness.

<Domes­tic Mar­ket>

In the domes­tic mar­ket, plans involve sell­ing nano health sup­ple­ments. The prod­ucts are cur­rent­ly in the process of reg­is­tra­tion with the Korea Food and Drug Admin­is­tra­tion. After com­ple­tion of reg­is­tra­tion, sales of nano prod­ucts will occur through spe­cial­ized dis­trib­u­tors and self-sales chan­nels (such as online plat­forms).

Oth­er Notes/Details

Chi­nese phar­ma­ceu­ti­cal com­pa­ny pri­or­i­tizes the ini­tial export of nano-cal­ci­um prod­ucts.